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Abstract 
BACKGROUND: Erysipelas is a common infectious skin disease. A typical feature of erysipelas, especially on the 
lower limbs, is the tendency to reoccur and the study aimed to define the comorbidities associated with it. 
AIM: We aimed to investigate systemic and local comorbidities in patients diagnosed with erysipelas on the lower 
limbs. 
MATERIAL AND METHODS: We conducted a retrospectively-prospective, population-based cohort study which 
included all patients diagnosed with erysipelas on the lower limbs, during two years. Patients were divided into 
two groups: patients with first episode and patients with recurrent erysipelas. These two groups were compared, 
with particular emphasis on systemic and local comorbidities. 
RESULTS: The study included 313 patients, of which 187 with the first episode of erysipelas and 126 with a 
recurrent. Regarding the analyzed systemic risk factors, the recurrent erysipelas was significantly associated with 
obesity (p < 0.0001), insulin dependent diabetes mellitus (p = 0.0015), history of malignant disease (p = 0.02) and 
tonsillectomy (p = 0.000001). For a p-value < 0.0001, significantly more frequent finding of peripheral arterial 
occlusive disease, chronic oedema/lymphoedema, fungal infections of the affected leg and chronic ulcer was 
confirmed in recurrent erysipelas. Neuropathy had 23% of the recurrent cases and 8.6% in patients without 
recurrence, and the difference was found to be significant for p = 0.0003. The only dissection of the lymph nodes 
was found more frequently in recurrent erysipelas (p = 0.017), but no associations with other analysed local 
surgery on the affected leg. Patients with recurrent erysipelas had ipsilateral coexisting dermatitis p = 0.00003 
significantly more frequent. Minor trauma often preceded the first episode of erysipelas p = 0.005. 
CONCLUSION: Identification and treatment of modifiable risk factors are expected to reduce the risk of a 
subsequent episode of erysipelas on the lower limbs. 
 
 
 
 
 
 
 
Introduction 
 
Erysipelas is an acute bacterial nonpurulent 
infection of the superficial layer of the skin, with 
significant inflammation of the lymphatic vessels 
(lymphangitis), whose main clinical feature is 
demarcated elevated, warm erythema with 
pronounced systemic symptoms [1], [2]. Cellulitis is a 
soft tissue infection that affects the deep dermis and 
subcutaneous tissue [2], [3], [4]. The historical 
distinction between cellulitis and erysipelas based on 
a different bacterial aetiology, and therefore 
therapeutic modalities, is outdated with the growth of 
evidence suggesting overlapping of these two entities 
[5], [6]. Epidemiological studies show an increase in 
the incidence of erysipelas [7], [8], [9]. It is thought to 
be 200 per 100,000 people per year, and there is no 
gender difference. The highest incidence was 
observed in the oldest age groups [9]. The most 
common anatomical localisation of erysipelas are the 
lower limbs [9]. Women are at greater risk for 
erysipelas on the trunk, and men are erysipelas on the 
lower limbs [9]. These infections are caused by 
streptococci, most commonly in Group A, but also 
from the groups B, C, F, or G. The diagnosis is 
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primarily clinical and is based empirically on the 
cutaneous manifestations, and systemic signs of 
infection [10]. Typically for erysipelas, especially the 
lower limbs, is the tendency to recur. The incidence of 
recurrent erysipelas varies from study to study. 
Namely, 10-30% of patients who have had erysipelas, 
will have relapses at different time intervals, several 
weeks to years [11], [12]. The relapse rate is 8% to 
20% per year [13]. In studies with a longer follow-up 
period, the rate of relapse is significantly higher, so in 
a retrospective three-year study it is more than 45% 
[14]. The recurrent erysipelas of the lower limbs is 
thought to be a result of the repetitive bacterial 
invasion of the skin through injuries to its protective 
barrier [14]. Accordingly, the potential points of entry 
of the infection were analyzed as risk factors for 
relapse in several clinical studies-disruption of the 
cutaneous barrier (ulcer, trauma), coexisting 
dermatoses of the lower limbs, lymphoedema, 
surgical interventions of the lymphatic/venous system, 
peripheral arterial occlusive disease, chronic venous 
insufficiency [8], [12], [15]. General risk factors include 
obesity, history of malignant disease and diabetes 
mellitus and smoking [12], [13], [14], [15], [16], [17], 
[18]. Treatment for an initial and recurrent episode of 
erysipelas do not differ and are described in several 
existing protocols [19], [20], [21], [22]. These protocols 
reinforce the significance of long-term antibiotic 
prophylaxis as a method for the reduction of recurrent 
erysipelas [23], [24], [25], but proclaim as well 
rigorous control of predisposing risk factors [13], [14], 
[16], [17]. 
We aimed to investigate systemic and local 
comorbidities in patients diagnosed with erysipelas on 
the lower limbs. 
 
 
Methods 
 
We conducted a retrospectively-prospective, 
population-based cohort study, conducted in a 
dermatology department in two years. All patients 
aged ≥ 18 years were recruited, with a diagnosis of 
acute erysipelas on the lower limbs. All types of 
necrotising skin and soft tissue infections (SSTI) have 
been excluded, skin infections in severely 
immunocompromised patients, and infectious 
complications of severe injuries to soft tissues. 
Patients with a first episode of erysipelas on the lower 
extremities were followed for at least one year from 
the initial episode, for the development of a recurrent 
one.  
Upon completion of the study and the follow-
up period, patients were divided into two groups, 
cohorts. First group (no recurrence group – NE)-
patients with the first episode of erysipelas defined 
only on clinical findings which included the area of 
erythema, swelling, warmth and pain, fever was not 
needed to meet the definition and did not experience 
a recurrent episode during the follow-up period. 
Second group-patients with recurrent erysipelas (RE), 
defined as a second/multiple episodes of erysipelas 
that meets the criteria of the first episode, at the same 
anatomical localisation, at least 1 month to one year 
from the initial diagnosis. This group will also include 
all patients with at least a second episode that has 
occurred during the study and out of the study 
(through anamnestic data or medical documentation 
for it). These two groups will be compared with 
particular emphasis on general and local risk 
factors/comorbidities. The required data for all 
recruited patients was obtained through clinical 
examination and patient interview, as well as medical 
records. The analysed variables were classified in 
local and general risk factor/comorbidities. Obesity is 
defined if BMI ≥ 30 [26]. Alcohol abuse is considered if 
the consumption of 14 units of alcohol per week is 
exceeded-in men and 7 units weekly for women [27].  
Point of entry was detected by clinical 
examination (wound, chronic ulcer, coexisting chronic 
pruritic dermatoses and fungal infections of the 
ipsilateral extremity). Chronic oedema/lymphoedema 
defined as chronic progressive swelling of the affected 
lower limb longer than 3 months [28] present on 
clinical examination or in the medical records. The 
following variables will be considered present if 
pointed in an interview or medical records-history of 
regional surgery; neurological diseases, history of 
phlebitis, diabetes mellitus, chronic renal failure, 
hepatic cirrhosis, cardiovascular diseases, history of 
malignancy, rheumatic and autoimmune diseases, 
peripheral arterial occlusive disease (PAOD), 
chronic venous insufficiency (CVI). Regarding 
statistics, the Kolmogorov-Smirnov test was used to 
test the distribution of data. The categorical variables 
are represented by distribution on frequencies. 
Quantitative variables with symmetric distribution are 
shown with mean values, and the media was used to 
display quantitative data with asymmetric distribution. 
Pearson Chi-square test, Yates Pearson Chi-square 
test (Student t-test for independent samples and 
Mann-Whitney test) were used to compare groups 
with first and recurrent erysipelas. The statistical 
significance was defined on the level of p < 0.05. 
 
 
Results 
 
Comparison of general  and local risk 
factors between 
The study included 313 subjects, of which 187 
were with a first episode of erysipelas (NE), and 126 
with recurrent erysipelas (RE). 
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Table 1: Comparison of comorbidities – general risk factors 
Variable Ne group Re group P-level 
Bmi 
Mean ± SD 30.01 ± 16.5 31.49 ± 6.5 P = 0.34 
Min - max 20.8 – 247 22.7 – 53.8 
Obesity  65 (34.76) 73 (57.94) P < 0.0001 
Diabetes mellitus     
Insulin dependant 39 (20.86) 48 (38.10) P = 0.0015 
On oral hypoglycemic agents 38 (20.32) 27 (21.43)  
Chronic kidney disease 9 (4.81) 8 (6.35) P = 0.56 
Cirrhosis hepatis  4 (2.14) 5 (3.97) P = 0.34 
History of malignancy  10 (5.35) 16 (12.7) P = 0.02 
Autoimmune disease 
Tonsilectomy  
4 (2.14) 
4.8 (9) 
5 (3.97) 
23.8 (30) 
P = 0.34 
P = 0.000001 
Аlcohol excess 28 (14.97) 16 (12.7) P = 0.57 
I.v. drug use  0 3 (2.38) P = 0.13 
Actueal smoking  42 (22.46) 35 (27.78) P = 0.28 
Cerebro vascular disease  4 (2.14) 5 (3.97) P = 0.34 
Copd  10 (5.35) 11 (8.73) P = 0.24 
Congesticve heart failure  42 (22.46) 33 (26.19) P = 0.45 
Ischaemic heart disease  21 (11.23) 23 (18.25) P = 0.08 
 
All the analyzed systemic risk factors (Table 
1), with the exception of alcoholism, were more 
commonly reported in RE patients, but a significant 
difference between the two groups was confirmed 
regarding this risk factors-obesity (p < 0.0001), 
diabetes mellitus (p = 0.0015), history of malignant 
disease (p = 0.02) and tonsillectomy (p = 0.000001) 
(Figure 1). 
 
Figure 1: Graphic representation of general risk factors in the two 
cohorts 
 
About 34.8% of patients with NE were obese, 
and 57.9% were patients with RE. Insulin-dependent 
DM had 20.9% of patients in the NE group and 38.1% 
with RE. 5.35% of the NE patients had a history of the 
malignant disease and 12.7% in the RE group. 
Tonsillectomy was performed in 4.8% of patients 
without and 23.8% of patients with RE.  
Table 2: Comparison of comorbidities – local risk factors 
Variable  NE group RE group p-level 
CVI 92 (49.2) 65 (51.59) P = 0.68 
PAOD 41 (21.93) 52 (41.27) P < 0.0001 
Chronic oedema/lymphoedema 64 (34.22) 109 (86.51) P < 0.0001 
History of an ulcer 24 (12.83) 64 (50.79) P < 0.0001 
History of flebitis 44 (23.53) 35 (27.78) P = 0.39 
Neuropathy 16 (8.56) 29 (23.02) P = 0.0003 
The surgical intervention of the blood and lymph. Vessels 
Saphenectomy  6 (3.21) 11 (8.73) P = 0.08 
Endovascular and other surgical intervention 
of the blood and lymph.Vessels 
26 (13.9) 20 (15.87)  
Local orthopaedic surgery     
Endoprotesis of knee and hip joint 8 (4.28) 7 (5.56) P = 0.051 
Fractures or other orthopaedic interventions 14 (7.49) 20 (15.87)  
Dissection of regional lymph nodes 1 (0.53) 7 (5.56) P = 0.017 
Surgery of the skin and soft tissue     
Skin grafting 1 (0.53) 5 (3.97)  
incision, drainage and other procedures 1 (0.53) 4 (3.17)  
Fungal infection     
Onichomycosis 7 (3.74) 25 (19.84) P < 0.0001 
Tinea pedis 21 (11.23) 41 (32.54)  
Preceding trauma 54 (28.88) 19 (15.08) P = 0.005 
Chronic ulcer 29 (15.51) 48 (38.1) P < 0.0001 
Ipsilateral coexisting dermatitis  49 (26.2) 62 (49.21) P = 0.00003 
Peripheral arterial occlusive disease (PAOD), 
chronic oedema/lymphoedema, history of an ulcer, 
neuropathy, lymph node dissection, preceding trauma, 
chronic ulcer fungal infections and coexisting 
dermatitis on the ipsilateral are local risk factors with 
significantly different representation in both cohorts 
(Table 2). For p < 0.0001 values, significantly more 
frequent finding of PAOD was confirmed in RE (51.6% 
vs 49.2%) in NE patients, chronic edema/ 
lymphoedema (86.5% vs 34.2%), fungal infections of 
the affected limb t (52.4% vs 15%), and chronic ulcer 
(38.1% vs 15.5%). Consecutive. With p < 0.0001 
significance, patients with recurrent erysipelas had a 
significantly more frequent history of an ulcer, 
compared with patients with NE (50.8% vs 12.8%). 
Neuropathy had 23% of patients with RE, and 8.6% in 
a patient with no recurrence and the difference was 
confirmed as significant for p = 0.0003. Dissection of 
lymph nodes had 8 patients, one without relapse and 
7 with recurrent erysipelas (p = 0.017). Patients with 
RE had significantly more frequent ipsilateral 
coexisting dermatitis (49.2% vs 26.2%, p = 0.00003). 
Minor trauma significantly preceded NE, (28.9% vs 
15.1%, p = 0.005). 
 
Figure 2: Graphic representation of local risk factors in the two 
cohorts  
 
 
 
Discussion 
 
The recurrence rate of erysipelas is almost 
30% in a 2-4-year period [29]. There are only a few 
studies that analyze the risk factors in recurrent 
erysipelas, some of the results of our study are 
consistent with them [12], [13], [14], [15], [16], [17], 
[18], [30].In this study, we included 313 patients 
throughout two years, of which 187 were the first 
episode of erysipelas, and 126 with recurrent 
erysipelas. The study was a retrospective-prospective 
population-based cohort, and the collected data are 
with particular emphasis on systemic and local risk 
factors and with the primary goal to compare patients 
with first (NE) and recurrent erysipelas (RE). The 
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study included all patients with erysipelas on the lower 
extremities, hospitalised and outpatient, avoiding bias 
in patient selection; however, hospitalised patients are 
more likely to be older and have more comorbidities. 
In our cohort of RE, significantly more frequent 
systemic risk factors were-obesity, history of 
malignant disease, which correlates to other studies 
[8], [13], [14], [15]. Diabetes in the RE is present with 
38.1% vs 20.9% in NE group (p < 0.001) and was 
strongly associated with recurrent erysipelas. In other 
studies [14], [17] this association has not been 
established. However, Harris et al. suggested an 
association with glucose intolerance [31]. Diabetes 
affects the healing process [32]. Hyperglycemia 
reduces the function of neutrophils and monocytes 
through impairment in the immune system cascade, 
primarily chemotaxis, adherence, and phagocytosis 
[33], [34]. People with diabetes are generally at 
greater risk of infection with certain microorganisms, 
in particular, group A and B streptococci and 
Staphylococcus aureus [35]. This study confirms 
tonsillectomy (p = 0.000001) as a risk factor for 
relapse, previously suggested by a study by Karppelin 
et al., from 2013 [18]. The ability of the streptococcus 
to survive intracellularly is suggested as a mechanism 
in recurrent tonsilitis and is likely the reason for the 
recurrent nature of erysipelas [36], [37], [38]. The 
most significant risk factors are local-Chronic 
oedema/lymphedema, history of ulcer, coexisting 
ipsilateral dermatitis, PAOD, chronic ulcer, fungal 
infections of the ipsilateral limb-all significant in other 
studies [12], [13], [14], [15], [16], [17]. In most of the 
patients who were involved in our study, the point of 
entry could be identified. The disruption of the 
cutaneous barrier is repeatedly referred to as a risk 
factor, namely in relation to fungal infections it is 
considered that they do not cause erysipelas, but in 
many cases of erysipelas of the lower limbs, the 
responsible streptococci are residents in the 
interdigital spaces, when they are macerated, 
presented with regards and fissures [39], [40], [41]. 
Recurrent episodes [40] have been discontinued the 
treatment of tinea pedis as a point of entry. 
Sometimes, the streptococcal reservoir is the anal 
canal or vagina, especially in patients with previous 
gynaecological carcinoma treated with surgical and 
radiotherapy [42]. However, only the disruption of the 
skin barrier usually does not lead to the onset of 
infection. It is considered that there must precede 
damage to the subcutaneous tissue and lymphatics. 
The authors agree that damage to the lymphatic 
system plays a key role in the development of acute 
cellulite on the lower limbs. In particular, damage to 
the venous and lymphatic system predisposes to the 
creation of an environment suitable for bacterial 
colonization for infections caused by β-haemolytic 
streptococci [12], [13], [43]. The lymphatic system 
plays a central role in the host's defence against skin 
infections and soft tissue. The damaged lymphatic 
clearance for microbial antigens and inflammatory 
mediators is proposed as a mechanism leading to a 
self-sustaining vicious circle of inflammation [44], [45]. 
In our study, the significance of CVI was not 
confirmed as a predictive risk factor, which is the case 
of multiple studies [12], [14], [30]. We’ve concluded 
that the reason is that the institution in which this 
study was conducted is specialised in the treatment 
and care of chronic wounds. All patients with first 
episode of erysipelas and CVI, were educated about 
the benefits and use of the appropriate compressive 
stockings/bandage (for each patient with CVI a 
compression bandage was applied during 
hospitalization) as well as skin care especially for 
lipodermatosclerosis and stasis dermatitis that is 
common in these patients and acts as point of entry. 
Surgical interventions of blood and lymphatic 
vessels, as well as orthopaedic surgery, have not 
been proven as significant risk factors, unlike in other 
studies [15], [41] except for local lymph node 
dissection. This is consistent with the risk factor 
history of malignant disease. Malignity can be 
complicated by venous and lymphatic compromise, 
directly due to tumour effects or indirectly due to 
radiotherapy, and it predisposes to streptococcal 
infection [43]. These results indicate that erysipelas 
should be considered as a recurrent, potentially 
chronic disease [4]. In all patients with acute 
erysipelas the lower extremities preventive measures 
are required to reduce the high incidence of recurrent 
disease. The extent of the required prophylaxis is 
unknown. However, prolonged antibiotic prophylaxis 
in patients at high risk has a role in preventing the 
recurrence [24]. The crucial element in prevention of 
recurrent infection is elimination of risk factors such as 
avoiding mechanical trauma, treatment of point of 
entry (chronic ulcers, tinea pedis, onychomycosis, 
pruritic dermatitis, and CVI), use of compressive 
stockings/bandages, lowering Body Mass Index (BMI) 
and rigorous glycemic control in diabetic patients.  
 
 
References 
 
1. Bisno AL, Stevens DL. Streptococcal infections of skin and soft 
tissues. New England Journal of Medicine. 1996; 334(4):240–6. 
https://doi.org/10.1056/NEJM199601253340407 PMid:8532002  
2. Swartz M. Cellulitis. N Engl J Med. 2004; 350:904–12. 
https://doi.org/10.1056/NEJMcp031807 PMid:14985488   
3. Raff AB, Kroshinsky D. Cellulitis: a review. JAMA. 2016; 
316(3):325–37. https://doi.org/10.1001/jama.2016.8825 
PMid:27434444  
 
4. Dalal A, Eskin‐Schwartz M, Mimouni D, Ray S, Days W, Hodak 
E, Leibovici L, Paul M. Interventions for the prevention of recurrent 
erysipelas and cellulitis. Cochrane Database of Systematic 
Reviews. 2017; 6:CD009758. 
https://doi.org/10.1002/14651858.CD009758.pub2 
 
5. Blackberg A, Trell K, Rasmussen M. Erysipelas, a large 
retrospective study of aetiology and clinical presentation. BMC 
Infect Dis. 2015; 15:402. https://doi.org/10.1186/s12879-015-1134-
2 PMid:26424182 PMCid:PMC4590694 
 
Brishkoska Boshkovski et al. Comorbidities as A Risk Factors for Acute and Recurrent Erysipelas 
_______________________________________________________________________________________________________________________________ 
_______________________________________________________________________________________________________________________________ 
Open Access Maced J Med Sci.                                                                                                                                                                                                         5 
 
6. Gunderson CG, Martinello RA. A systematic review of 
bacteremias in cellulitis and erysipelas. J Infect. 2012; 64:148-55. 
https://doi.org/10.1016/j.jinf.2011.11.004 PMid:22101078  
 
7. Goettsch WG, Bouwes Bavinck JN, Herings RM. Burden of 
illness of bacterial cellulitis and erysipelas of the leg in the 
Netherlands. J Eur Acad Dermatol Venereol. 2006; 20:834e9. 
 
8. Bartholomeeusen S, Vandenbroucke J, Truyers C, Buntinx F. 
Epidemiology and comorbidity of erysipelas in primary care. 
Dermatology. 2007; 215(2):118-22. 
https://doi.org/10.1159/000104262 PMid:17684373  
 
9. Ellis Simonsen SM, Van Orman ER, Hatch BE, Jones SS, Gren 
LH, Hegmann KT, et al. Cellulitis incidence in a defined population. 
Epidemiology & Infection. 2006; 134(2):293–9. 
https://doi.org/10.1017/S095026880500484X PMid:16490133 
PMCid:PMC2870381 
 
10. Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein 
EJC, Gorbach SL, et al. Practice guidelines for the diagnosis and 
management of skin and soft tissue infections: 2014 update by the 
Infectious Diseases Society of America. Clin Infect Dis. 2014; 
59:e10–52. https://doi.org/10.1093/cid/ciu296 
 
11. Eriksson B, Jorup-Rönström C, Karkkonen K, Sjöblom AC, 
Holm SE. Erysipelas: clinical and bacteriologic spectrum and 
serological aspects. Clinical infectious diseases. 1996; 23(5):1091-
8. https://doi.org/10.1093/clinids/23.5.1091 PMid:8922808  
 
12. Dupuy A, Benchikhi H, Roujeau JC, et al. Risk factors for 
erysipelas of the leg (cellulitis): case-control study. BMJ. 1999; 
318:1591–4. https://doi.org/10.1136/bmj.318.7198.1591 
PMid:10364117 PMCid:PMC28138 
 
13. Mcnamara DR, Tlyjeh IM, Berbari EF, Lahr BD, Martinez J, 
Mirzoyev SA, et al. A predictive model of recurrent lower extremity 
cellulitis in a population-based cohort. Arch Intern Med. 
2007;167(7):709-15. https://doi.org/10.1001/archinte.167.7.709 
PMid:17420430  
 
14. Pavlotsky F, Amrani S, Trau H. Recurrent erysipelas: risk 
factors: Risikofaktoren für Rezidiverysipele. JDDG: Journal der 
Deutschen Dermatologischen Gesellschaft. 2004; 2(2):89-95. 
https://doi.org/10.1046/j.1439-0353.2004.03028.x PMid:16279242  
 
15. Karppelin M, Siljander T, Vuopio-Varkila J, Kere J, Huhtala H, 
Vuento R, Jussila T, Syrjanen J: Factors predisposing to acute and 
recurrent bacterial non-necrotizing cellulitis in hospitalized patients: 
a prospective case-control study. Clinical Microbiology & Infection. 
2010; 16(6):729–34. https://doi.org/10.1111/j.1469-
0691.2009.02906.x PMid:19694769  
 
16. Cox NH. Oedema as a risk factor for multiple episodes of 
cellulitis/ erysipelas of the lower leg: a series with community 
follow-up. Br J Dermatol. 2006;155(5):947-50. 
https://doi.org/10.1111/j.1365-2133.2006.07419.x PMid:17034523  
 
17. Lewis SD, Peter GS, Gomez-Marin O, Bisno AL. Risk factors 
for recurrent lower extremity cellulitis in a US Veterans Medical 
Center population. The American journal of the medical sciences. 
2006; 332(6):304-7. https://doi.org/10.1097/00000441-200612000-
00002 PMid:17170620  
 
18. Karppelin M, Siljander T, Huhtala H, Aroma A, Vuopio J, 
Hannula-Jouppi K, et al. Recurrent cellulitis with benzathine 
penicillin prophylaxis associated with diabetes and psoriasis. 
European Journal of Clinical Microbiology& Infectious Diseases. 
2013; 32(3):369–72. https://doi.org/10.1007/s10096-012-1751-2 
PMid:23007460  
 
19. Eron LJ, Lipsky BA, Low DE, Nathwani D, Tice AD, Volturo GA: 
Managing skin and soft tissue infections: expert panel 
recommendations on key decision points. J Antimicrob Chemother. 
2003; 52(Suppl 1):i3–i17. https://doi.org/10.1093/jac/dkg466 
PMid:14662806  
 
20. Guidelines and Audit Implementation Network. CREST 
guidelines on the management of cellulitis in adults. Belfast, GAIN, 
June 2005. 
 
21. British Lymphology Society (BLS). Consensus Document on 
the Management of Cellulitis in Lymphoedema. Revised Cellulitis 
Guidelines, 2016. www.lymphoedema.org/images/ 
pdf/CellulitisConsensus.pdf (accessed May 2017). 
 
22. Societe Francaise de Dermatologie. Erysipelas and necrotizing 
fasciitis [Erysipele et fasiite necrosante: prise encharge]. Annales 
de dermatologie et de vénéréologie. 2001; 128:463–82. 
PMid:11319379  
 
23. Mason JM, Thomas KS, Crook AM, Foster KA, Chalmers JR, 
Nunn AJ, et al. Prophylactic antibiotics to prevent cellulitis of the 
leg: economic analysis of the PATCH I & II trials. PLoS One. 2014; 
9:e82694. https://doi.org/10.1371/journal.pone.0082694 
PMid:24551029 PMCid:PMC3925077 
 
24. Thomas KS, Crook AM, Nunn AJ, Foster KA, Mason JM, 
Chalmers JR, et al. Penicillin to prevent recurrent leg cellulitis. N 
Engl J Med. 2013; 368:1695e703. 
 
25. Oh CC, Ko HC, Lee HY, et al. Antibiotic prophylaxis for 
preventing recurrent cellulitis: a systematic review and meta-
analysis. J Infect. 2014; 69:26–34. 
https://doi.org/10.1016/j.jinf.2014.02.011 PMid:24576824  
 
26. World Health Organization (WHO). Obesity: preventing and 
managing the global epidemic. WHO Technical Report Series, No. 
894. Geneva: WHO, 2000. 
 
27. National Intstitutes of Health. 10th Special report to the U.S. 
Congress on alcohol and health: highlights from current research 
from the Secretary of Health and Human Services, NIH publication 
no. 00-1583. US Department of Health and Human Services, 
Public Health Service, National Institutes of Health, National 
Institute on Alcohol Abuse and Alcoholism, 2000:429–30. 
 
28. Moffatt CJ, Franks PJ, Doherty DC, Williams AF, Badger C, 
Jeffs E, Bosanquet N, Mortimer PS. Lymphoedema: an 
underestimated health problem. Qjm. 2003; 96(10):731-8. 
https://doi.org/10.1093/qjmed/hcg126 PMid:14500859  
 
29. Jorup-Rönström C, Britton S. Recurrent erysipelas: 
predisposing factors and costs of prophylaxis. Infection. 1987; 
15:105-6. https://doi.org/10.1007/BF01650206 PMid:3110071  
 
30. Tay EY, Fook-Chong S, Oh CC, Thirumoorthy T, Pang SM, Lee 
HY. Cellulitis Recurrence Score: A tool for predicting recurrence of 
lower limb cellulitis. Journal of the American Academy of 
Dermatology. 2015; 72(1):140-5. 
https://doi.org/10.1016/j.jaad.2014.08.043 PMid:25443627  
 
31. Harris RA, Hardman DT, Brown AR. CELLULITE AND THE 
OCCULT DIABETIC. Australian and New Zealand journal of 
surgery. 1996; 66(3):175-7. https://doi.org/10.1111/j.1445-
2197.1996.tb01151.x PMid:8639138  
 
32. Gibran NS, Jang YC, Isik FF, et al. Diminished neuropeptide 
levels contribute to the impaired cutaneous healing response 
associated with diabetes mellitus. J Surg Res. 2002; 108(1):122–8. 
https://doi.org/10.1006/jsre.2002.6525 PMid:12443724  
 
33. Pozzilli P, Leslie RD. Infections and diabetes: mechanisms and 
prospects for prevention. Diabet Med. 1994; 11(10):935–41. 
https://doi.org/10.1111/j.1464-5491.1994.tb00250.x PMid:7895457  
 
34. Delamaire M, Maugendre D, Moreno M, et al. Impaired 
leucocyte functions in diabetic patients. Diabet Med. 1997; 
14(1):29–34. https://doi.org/10.1002/(SICI)1096-
9136(199701)14:1<29::AID-DIA300>3.0.CO;2-V 
 
35. Factor SH, Levine OS, Schwartz B, Harrison LH, Farley MM, 
McGeer A, Schuchat A. Invasive group A streptococcal disease: 
risk factors for adults. Emerging infectious diseases. 2003; 
9(8):970-7. https://doi.org/10.3201/eid0908.020745 
PMid:12967496 PMCid:PMC3020599 
 
36. O'Neill AM, Thurston TL, Holden DW. Cytosolic Replication of 
Group A Streptococcus in Human Macrophages. MBio. 2016; 
7:e00020-16. https://doi.org/10.1128/mBio.00020-16 
 
37. Österlund A, Popa R, Nikkilä T, Scheynius A, Engstrand L. 
Intracellular reservoir of Streptococcus pyogenes in vivo: a 
possible explanation for recurrent pharyngotonsillitis. The 
Laryngoscope. 1997; 107(5):640-7. 
https://doi.org/10.1097/00005537-199705000-00016 
PMid:9149167  
 
38. Sendi P, Graber P, Johansson L, Norrby-Teglund A, Zimmerli 
W. Streptococcus agalactiae in relapsing cellulitis. Clinical 
infectious diseases. 2007; 44(8):1141-2. 
 
Clinical Science 
_______________________________________________________________________________________________________________________________ 
 
_______________________________________________________________________________________________________________________________ 
6                                                                                                                                                                                                   https://www.id-press.eu/mjms/index 
 
https://doi.org/10.1086/513034 PMid:17366471  
39. Semel JD, Goldin H. Association of athlete's foot with cellulitis 
of the lower еxtremities: diagnostic value of bacterial cultures of 
ipsilateral interdigital space samples. Clin Infect Dis. 1996; 
23(5):1162–4. https://doi.org/10.1093/clinids/23.5.1162 
 
40. Baddour, LM and Bisno, AL (1984): Recurrent cellulitis after 
coronary bypass surgery. Association with superficial fungal 
infection in saphenous venectomy limbs. JAMA. 1984; 
251(8):1049–52. 
https://doi.org/10.1001/jama.1984.03340320035023 PMid:6607365  
 
41. Björnsdottir, S, Gottfredsson, M, Thorisdottir, AS, Gunnarsson, 
GB, Rikardsdottir, H, Kristjansson, M and Hilmarsdottir, I: Risk 
factors for acute cellulitis of the lower limb: a prospective case-
control study. Clin Infect Dis. 2005; 41(10):1416-22. 
https://doi.org/10.1086/497127 PMid:16231251  
 
42. Eriksson BK. Anal colonization of group G beta-hemolytic 
streptococci in relapsing erysipelas of the lower extremity. Clin  
Infect Dis. 1999; 29(5):1319–20. https://doi.org/10.1086/313467 
PMid:10524984  
43. Baddour LM, Bisno AL. Non-group A beta-hemolytic 
streptococcal cellulitis: association with venous and lymphatic 
compromise. Am J Med. 1985; 79(2):155-159. 
https://doi.org/10.1016/0002-9343(85)90003-8 
 
44. Smith RD, Spittell JA, Schirger A. Secondary lymphedema of 
the leg: its characteristics and diagnostic implications. JAMA. 1963; 
185:80–2. https://doi.org/10.1001/jama.1963.03060020040018 
PMid:13989558  
 
45. Dreyer G, Noroes J, Figueredo-Silva J, Piessens WF. 
Pathogenesis of lymphatic disease in bancroftian filariasis: a 
clinical perspective. Parasitol Today. 2000; 16(12):544–8. 
https://doi.org/10.1016/S0169-4758(00)01778-6 
 
 
